NASDAQ:MNTA
Delisted

Momenta Pharmaceuticals Stock News

etoro logo Buy MNTA
*Your capital is at risk
$52.48
+0 (+0%)
At Close: May 27, 2022
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 37,575 shares of the stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $30.56, for a total
Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) hit a new 52-week high on Monday after JPMorgan Chase & Co. raised their price target on the stock from $37.00 to $42.00. JPMorgan Chase & Co. cur
Ever wondered how to buy shares in Mylan NV in Australia? We explain how and compare the best share trading platforms.
Here's a roundup of top developments in the biotech space over the last 24 hour. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) ADC Therapeutics SA (NYSE:...
Momenta (MNTA) stock up on the announcement of positive data from a mid-stage study on nipocalimab for the indication of gMG.

Company News for Jun 16, 2020

01:58pm, Tuesday, 16'th Jun 2020
Companies in the news are: JKS, MNTA, CAI, CATM
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 16) * Applied Molecular Transport Inc (NASDAQ: AMTI) (wen
Read about the biggest pharmaceutical development and pricing stories from the past week in KHN’s Prescription Drug Watch roundup.

6 Stocks That Could Jump Higher

12:00am, Tuesday, 16'th Jun 2020
Stocks Analysis by Harry Boxer covering: Celsion Corp, Celldex Therapeutics Inc, Digital Ally Inc, Dynavax Technologies Corporation. Read Harry Boxer's latest article on Investing.com
Positive phase 2 clinical trial data puts the biotech's lead drug candidate on a good path forward.
Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced positive topline
In a mid-stage clinical trial, an experimental Momenta medicine significantly improved the symptoms of patients with generalized myasthenia gravis.
Economic optimism has broadened the market rally. Small caps had lagged significantly and are now catching-up as they narrow the performance gap. The Federal Re
Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE